Closing VRUS (Pharmasset) underperform
Another prediction came true, to a degree even beyond my expectations. Unfortunately work is busy today and I missed the top, losing about 30 CAPS points in each direction as I reversed to a thumbs down. Hepatitis C is clearly proving itself as an agent of change. I expect the next major change for Pharmasset will be downward, however, as R7128 is either shown to cause hepatotoxicity or is simply not as effective as hoped for in later stage trials. See Vertex or Idenix for similar stories.